Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

The S&P 500 jumped 1% on Friday, Jan. 17, 2025, heading into the long weekend on a high note as prospects rebounded for ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

Taiwan Semiconductor Manufacturing reports a 57% jump in profit on strong demand for hardware to power AI systems.

Pope Francis fell Thursday and hurt his right arm, the Vatican said, just weeks after another apparent fall resulted in a bad ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...